Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
P/B ratio for Biofrontera Inc. (BFRI)
P/B ratio as of 2023: 0.89
According to Biofrontera Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.89. At the end of 2022 the company had a P/B ratio of 0.81.
P/B ratio history for Biofrontera Inc. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.89 |
| 2022 | 0.81 |
| 2021 | 11.34 |
| 2020 | 8.78 |
| 2019 | -1.77 |